Clinical trial
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
NCT03009201 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
- Lead sponsor
- OHSU Knight Cancer Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 10, 2017
- Completion date
- June 30, 2023
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced soft tissue sarcoma, locally advanced angiosarcoma, locally advanced leiomyosarcoma, locally advanced liposarcoma, locally advanced malignant peripheral nerve sheath tumor, locally advanced myxofibrosarcoma, locally advanced undifferentiated pleomorphic sarcoma, metastatic angiosarcoma, metastatic epithelioid sarcoma, metastatic fibrosarcoma, metastatic liposarcoma, metastatic malignant peripheral nerve sheath tumor, metastatic myxofibrosarcoma, metastatic soft tissue sarcoma, metastatic synovial sarcoma, metastatic undifferentiated pleomorphic sarcoma, myxofibrosarcoma, pleomorphic rhabdomyosarcoma, stage iii soft tissue sarcoma ajcc v7, stage iv soft tissue sarcoma ajcc v7, undifferentiated (embryonal) sarcoma, unresectable leiomyosarcoma, unresectable liposarcoma, unresectable malignant peripheral nerve sheath tumor, unresectable soft tissue sarcoma, unresectable synovial sarcoma, unresectable undifferentiated pleomorphic sarcoma